4//SEC Filing
Ragosa Mark 4
Accession 0001835458-25-000007
CIK 0001730430other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 5:06 PM ET
Size
17.2 KB
Accession
0001835458-25-000007
Insider Transaction Report
Form 4
Ragosa Mark
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-12-08$11.10/sh+16,164$179,420→ 47,250 total - Exercise/Conversion
Class A Ordinary Share
2025-12-08$11.97/sh+16,165$193,495→ 63,415 total - Exercise/Conversion
Class A Ordinary Share
2025-12-08$10.76/sh+10,512$113,109→ 73,927 total - Sale
Class A Ordinary Share
2025-12-08$41.49/sh−42,841$1,777,473→ 31,086 total - Exercise/Conversion
Share Option
2025-12-08−16,164→ 5,388 totalExercise: $11.10Exp: 2032-04-06→ Class A Ordinary Share (16,164 underlying) - Exercise/Conversion
Share Option
2025-12-08−16,165→ 12,123 totalExercise: $11.97Exp: 2032-08-31→ Class A Ordinary Share (16,165 underlying) - Exercise/Conversion
Share Option
2025-12-08−10,512→ 14,016 totalExercise: $10.76Exp: 2033-03-31→ Class A Ordinary Share (10,512 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.20 and $42.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
- [F4]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
- [F5]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
Documents
Issuer
Kiniksa Pharmaceuticals International, plc
CIK 0001730430
Entity typeother
Related Parties
1- filerCIK 0001835458
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 5:06 PM ET
- Size
- 17.2 KB